The MPC2 Knockout Raji Polyclonal Cells product offers a CRISPR/Cas9-edited polyclonal knockout cell population in the human Raji B lymphocyte line, designed for the targeted disruption of the MPC2 gene. This genetically modified cell pool provides a robust loss-of-function model for studying mitochondrial pyruvate carrier function without clonal selection, preserving biological heterogeneity. The polyclonal format ensures representation of diverse editing events while maintaining overall knockout efficacy, making it suitable for functional genomics and metabolic research.
Raji cells, derived from an EBV-positive Burkitt’s lymphoma, serve as an established model for B-cell malignancies, B-cell receptor signaling, apoptosis, and EBV biology. These lymphoblastoid cells exhibit robust proliferation and are widely used in immunological and cancer studies. Their metabolic profile and signaling networks make them an ideal host for investigating mitochondrial metabolism in hematopoietic cancers.
MPC2 encodes an essential subunit of the mitochondrial pyruvate carrier, which, in complex with MPC1, facilitates pyruvate import into the mitochondrial matrix. This process is critical for driving the TCA cycle and oxidative phosphorylation, linking glycolytic flux to ATP production. MPC2 expression is transcriptionally regulated by PPARGC1A, AMPK, c-Myc, and HIF1A, and its activity modulates downstream targets including TCA cycle enzymes (CS, IDH, SDH), ATP synthase (ATP5A1), and electron transport chain complexes. The carrier complex interacts with STOML2 and the mitochondrial protein import machinery. Disruption of MPC2 impairs pyruvate oxidation, leading to a compensatory increase in glycolysis and an altered NAD+/NADH ratio, a hallmark of the Warburg effect often observed in cancer cells.
In the Raji B-cell lymphoma context, MPC2 knockout perturbs the balance between oxidative metabolism and glycolysis, mirroring metabolic reprogramming events in aggressive hematological malignancies. This model is particularly valuable for dissecting how mitochondrial pyruvate transport influences tumor cell proliferation, survival, and response to metabolic stress. By disrupting a key node in cellular energy homeostasis, researchers can elucidate the role of MPC2-dependent metabolism in EBV-driven lymphomagenesis and explore therapeutic vulnerabilities associated with metabolic dysregulation.
Typical applications include metabolic flux analysis using Seahorse XF assays to measure oxygen consumption rate (OCR) and extracellular acidification rate (ECAR), targeted metabolomics via LC-MS, and quantification of ATP levels and mitochondrial membrane potential (JC-1/TMRM). The polyclonal knockout cells are also suited for drug screening of metabolic modulators, RNA-seq transcriptome profiling, and Western blot verification of OXPHOS complex expression. Researchers can investigate the Warburg effect in B-cell lymphoma, perform pyruvate uptake studies, and assess cell cycle and apoptosis by flow cytometry. For additional information, please contact Ascent Research.
